Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for Chronic Pain in Smokers
NCT07118332Phase 1Recruiting
- Sponsor
- Yale University
- Start
- Jul 2026
- Primary completion
- Oct 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin in chronic pain and Tobacco Use Disorder (TUD), sponsored by Yale University. Primary endpoint: Systematic Assessment for Treatment Emergent Events at Day 7. Started Jul 2026; status: recruiting.
02
Drugs
psilocybin
03
Conditions
chronic painTobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT07118332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07118332.